Abstract:That cancer cells show patterns of metabolism different from normal cells has been known for over 50 years. Yet, it is only in the past decade or so that an appreciation of the benefits of these changes has begun to emerge. Altered cancer cell metabolism was initially attributed to defective mitochondria. However, we now realize that most cancers do not have mitochondrial mutations and that normal cells can transiently adopt cancer-like metabolism during periods of rapid proliferation. Indeed, an encompassing, albeit somewhat simplified, conceptual framework to explain both normal and cancer cell metabolism rests on several simple premises. First, the metabolic pathways used by cancer cells and their normal counterparts are the same. Second, normal quiescent cells use their metabolic pathways and the energy they generate largely to maintain cellular health and organelle turnover and, in some cases, to provide secreted products necessary for the survival of the intact organism. By contrast, undifferentiated cancer cells minimize the latter functions and devote their energy to producing the anabolic substrates necessary to maintain high rates of unremitting cellular proliferation. Third, as a result of the uncontrolled proliferation of cancer cells, a larger fraction of the metabolic intermediates normally used by quiescent cells purely as a source of energy are instead channeled into competing proliferation-focused and energy-consuming anabolic pathways. Fourth, cancer cell clones with the most plastic and rapidly adaptable metabolism will eventually outcompete their less well-adapted brethren during tumor progression and evolution. This attribute becomes increasingly important as tumors grow and as their individual cells compete in a constantly changing and inimical environment marked by nutrient, oxygen, and growth factor deficits. Here, we review some of the metabolic pathways whose importance has gained center stage for tumor growth, particularly those under the control of the c-Myc (Myc) oncoprotein. We discuss how these pathways differ functionally between quiescent and proliferating normal cells, how they are kidnapped and corrupted during the course of transformation, and consider potential therapeutic strategies that take advantage of common features of neoplastic and metabolic disorders.

Hypoxia and Metabolism - Opinion - the Interplay Between Myc and Hif in Cancer

The cellular-centered view of hypoxia tumor microenvironment: Molecular mechanisms and therapeutic interventions

MYC-Induced Cancer Cell Energy Metabolism and Therapeutic Opportunities

Hypoxia Boosts Aerobic Glycolysis in Carcinoma: A Complex Process for Tumour Development

Cancer Cell Metabolism in Hypoxia: Role of HIF-1 as Key Regulator and Therapeutic Target

Metabolic profiling reveals potential metabolic markers associated with Hypoxia Inducible Factor-mediated signalling in hypoxic cancer cells

Hypoxia: Intriguing Feature in Cancer Cell Biology

The Role for Myc in Coordinating Glycolysis, Oxidative Phosphorylation, Glutaminolysis, and Fatty Acid Metabolism in Normal and Neoplastic Tissues

Tumor hypoxia and heterogeneity: Challenges and opportunities for the future

Central role of hypoxia-inducible factor-1α in metabolic reprogramming of cancer cells: A review

Therapeutic Targeting Hypoxia-Inducible Factor (HIF-1) in Cancer: Cutting Gordian Knot of Cancer Cell Metabolism

Metabolomic Investigations into Hypoxia-Mediated Metabolic Reprogramming of Pancreatic Cancer Cells

Hypoxia inducible factor (HIF) in the tumor microenvironment: friend or foe?

Romance of the three kingdoms in hypoxia: HIFs, epigenetic regulators, and chromatin reprogramming

Hypoxia Signaling in Cancer: Implications for Therapeutic Interventions

Hypoxia-Driven Effects in Cancer: Characterization, Mechanisms, and Therapeutic Implications

Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics

Hypoxia Dictates Metabolic Rewiring of Tumors: Implications for Chemoresistance

Tumor hypoxia: From basic knowledge to therapeutic implications

HIF-1α signaling: Essential roles in tumorigenesis and implications in targeted therapies

HIF-1-Dependent Reprogramming of Glucose Metabolic Pathway of Cancer Cells and Its Therapeutic Significance